Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia - 1 Jun 2020

Zhang Qing, Haider Mintallah, Al Ali Najla H, Lancet Jeffrey E, Epling-Burnette Pearlie K, List Alan F, Padron Eric, Komrokji Rami S

Abstract excerpt

BACKGROUND: Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower-risk myelodysplastic syndrome (MDS). Age, human leukocyte antigen (HLA)-DR15 positivity, and duration of transfusion dependence are putative clinical variables predictive for response. We investigated the effect of somatic gene mutations on response to IST in lower-risk MDS. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DR Serological Subtypes

Share to Immunosuppressive Agents

Share to Myelodysplastic Syndromes

Share to Phosphoproteins

Share to Predictive Value of Tests

Share to RNA Splicing Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 32179032
DOI: 10.1016/j.clml.2019.12.023
PMCID: PMC7771378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.PMID 32179032Read ↗

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review.Semantic proximity Read ↗

Mutations and karyotype predict treatment response in myelodysplastic syndromes.Semantic proximity Read ↗

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.Semantic proximity Read ↗

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Semantic proximity Read ↗

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.Semantic proximity Read ↗

Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemiaSemantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.Semantic proximity Read ↗

Lowering the boom on lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.